Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.

摘要: Acute heart failure remains a major cause of morbidity, and its treatment requires an increasing investment the health care system. Whereas success in treating chronic has been achieved over last decades, several pharmacological approaches for acute have introduced but failed to demonstrate any clinical benefit. Serelaxin is recombinant human relaxin-2 vasoactive peptide that causes systemic renal vasodilation. Data suggest benefits may be attributable potential combination multiple actions serelaxin, including improving systemic, cardiac, hemodynamics, protecting cells organs from damage via neurohormonal, anti-inflammatory, antiremodeling, antifibrotic, anti-ischemic, proangiogenic effects. Recently, number trials demonstrated serelaxin infusion 48 hours improved dyspnea with more rapid relief congestion during first days after admission failure. In addition, administration diminished renal, hepatic damage, which were associated long-term mortality. Available data support substantial significant promise as option patients This review focuses on pharmacology mechanisms action provides detailed discussion evidence this novel therapy